Menopause and Hormone Replacement Therapy (HRT): The Modern Reassessment

Deep-Dive Articles

Table of Contents

1. Deep-Dive Articles
2. Menopause Stages
3. Symptoms and Long-Term Effects
4. What Menopausal Hormone Therapy Is
5. Benefits — The Evidence
6. Risks — The Honest Picture
7. The Timing Hypothesis
8. Oral vs Transdermal
9. Types of Progestogen
10. Testosterone in Women
11. Non-Hormonal Options
12. Lifestyle Support
13. Connections
14. Featured Videos

Menopause Stages

• Perimenopause — The transition, typically starting in the mid-40s, when ovarian hormone production becomes erratic. Cycles shorten, lengthen, or skip. Symptoms often begin here.
• Menopause — Defined as 12 consecutive months without a menstrual period.
• Postmenopause — Every year thereafter. Symptoms may persist for years to decades.

Symptoms and Long-Term Effects

• Vasomotor symptoms (VMS). Hot flashes and night sweats affect roughly 75% of women and last a median of 7.4 years in total, and more than 11.8 years in women whose symptoms began before or early in perimenopause (Avis 2015).
• Sleep disturbance. Often secondary to VMS but also directly hormonal.
• Mood changes. Increased risk of depression, anxiety, irritability.
• Cognitive symptoms. Word-finding difficulty, brain fog, concentration loss — typically transient.
• Genitourinary syndrome of menopause (GSM). Vaginal dryness, painful intercourse, urinary frequency, recurrent urinary tract infections. Often overlooked but highly treatable with local estrogen.
• Bone loss. Rapid loss in the first 5–10 years after menopause, driving osteoporosis risk.
• Cardiovascular changes. Acceleration of atherosclerosis and lipid worsening.
• Weight redistribution. Increased visceral fat.
• Skin and hair changes. Thinning, dryness, reduced elasticity.

What Menopausal Hormone Therapy Is

MHT typically replaces estrogen (most often estradiol) and, in women with a uterus, a progestogen to protect the endometrium from estrogen-induced overgrowth that could otherwise lead to endometrial cancer. Women who have had a hysterectomy can take estrogen alone. Routes of administration include:

• Transdermal patch — applied twice weekly.
• Transdermal gel or spray — daily.
• Oral tablet — daily.
• Vaginal estrogen — cream, ring, or tablet for GSM specifically, with minimal systemic absorption.
• Micronized progesterone — oral bedtime capsule (also has mild sedating/anxiolytic effect).

Benefits — The Evidence

• Vasomotor symptoms. MHT is the most effective treatment, typically reducing hot flashes by 75–90%.
• Sleep and mood. Improvement often follows VMS reduction; some direct benefit.
• Bone health. MHT prevents postmenopausal bone loss and reduces hip, vertebral, and all fractures by roughly 25–40% in WHI data.
• Cardiovascular. When started within 10 years of menopause, MHT is associated with reduced coronary events in re-analyses and in the Danish DOPS trial.
• Diabetes. Reduces incident type-2 diabetes by roughly 20–30%.
• Genitourinary symptoms. Vaginal estrogen is first-line and highly effective.
• Colorectal cancer. Modest reduction in some analyses.
• Quality of life. Consistent improvement.

Risks — The Honest Picture

• Breast cancer. Combined estrogen-progestogen MHT increases breast-cancer risk modestly after 3–5 years of use (an additional ~1 case per 1000 women-years in the WHI). Estrogen-alone MHT in the WHI was associated with reduced breast-cancer incidence. Micronized progesterone appears lower risk than synthetic progestins.
• Venous thromboembolism (VTE). Oral estrogen roughly doubles VTE risk; transdermal estrogen does not raise VTE risk and is preferred in higher-risk women.
• Stroke. Small increase with oral estrogen, particularly in older initiators.
• Gallbladder disease. Increased risk with oral estrogen.
• Endometrial cancer. Prevented by adequate progestogen in women with a uterus.

The Timing Hypothesis

The WHI’s widely publicized harms were driven largely by women who initiated MHT more than 10 years past menopause or after age 60, when arterial plaques may already be established. Pooled evidence strongly supports that initiation within 10 years of menopause and under age 60 carries a favorable risk-benefit profile for most women, particularly when symptomatic. Initiation later is not always harmful but the benefit margin is narrower.

Oral vs Transdermal

Oral estrogen undergoes first-pass liver metabolism, raising clotting factors, triglycerides, sex-hormone-binding globulin, and inflammatory markers. Transdermal estrogen bypasses this and has not been associated with increased VTE or stroke risk. For most women, especially those with metabolic-syndrome features, migraine with aura, or VTE risk factors, transdermal is preferred.

Types of Progestogen

Micronized oral progesterone (Prometrium) is structurally identical to natural progesterone, has a mild sedating effect helpful at bedtime, and appears to have a better breast-cancer safety signal than synthetic progestins in European cohort studies. Synthetic progestins (e.g., medroxyprogesterone acetate) remain effective for endometrial protection but carry the breast-cancer signal seen in WHI. Levonorgestrel IUDs provide effective endometrial protection with minimal systemic exposure.

Testosterone in Women

Low-dose testosterone supplementation is evidence-based for hypoactive sexual desire disorder (HSDD) in postmenopausal women. Benefits for energy, mood, and cognition are claimed clinically but not strongly established in randomized trials. Doses used are roughly one-tenth of male replacement doses, typically delivered as a compounded cream. No testosterone product is U.S. Food and Drug Administration-approved for women in the U.S. as of this writing.

Non-Hormonal Options

• Fezolinetant (Veozah) — a neurokinin-3 receptor antagonist approved in 2023 specifically for moderate-to-severe hot flashes.
• Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) — paroxetine (Brisdelle) is U.S. Food and Drug Administration-approved; venlafaxine and escitalopram also help VMS.
• Gabapentin — helps hot flashes especially at night.
• Cognitive behavioral therapy — reduces the bother of symptoms meaningfully.
• Clinical hypnosis — has good trial evidence for VMS.
• Acupuncture — modest but consistent trial signal.

Lifestyle Support

• Regular aerobic and resistance training — improves bone density, metabolic health, mood, and sleep.
• Adequate dietary protein (1.2 g/kg of goal weight) to preserve muscle mass.
• Weight management — adipose tissue generates estrogen but also drives VMS in a complex way.
• Sleep hygiene and stress management.
• Reduce alcohol — a major VMS and breast-cancer-risk modifier.
• Calcium (1200 mg/day from food), vitamin D adequate, magnesium, and vitamin K2 for bone.

Connections

• Reproductive Medicine
• Menopause: Why the Hormones Fall and What Changes — interactive animation
• Perimenopause Symptom Tracker and Hormonal Testing
• Micronized Progesterone vs Synthetic Progestins
• Estradiol Formulations: Patch, Gel, Oral Routes
• Hormone Replacement Therapy Risks: Breast Cancer, Clots and Stroke
• Testosterone Therapy for Women
• Vasomotor Symptoms: Hot Flashes and Night Sweats
• Bone Loss Prevention and Hormone Replacement Therapy
• Genitourinary Syndrome of Menopause and Vaginal Estrogen
• Non-Hormonal Options: Selective Serotonin Reuptake Inhibitors, Gabapentin, Fezolinetant
• Perimenopause
• Calcium
• Depression
• Osteoporosis
• Hormone Panel
• Insomnia
• Cardiovascular Disease
• Vitamin D3
• Vitamin K
• Breast Cancer
• Ovarian Cancer
• Endometrial Cancer
• PMS and PMDD
• Urinary Incontinence
• Herbs covered on this site that discuss this condition: Red Clover · Motherwort · Sage (Salvia officinalis)
• Menopause Management

↑ Back to Table of Contents

Key Research Papers

1. Rossouw JE, Anderson GL, Prentice RL, et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA — PubMed PMID: 12117397
2. Manson JE, Chlebowski RT, Stefanick ML, et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA — PubMed PMID: 24084921
3. Rossouw JE, Prentice RL, Manson JE, et al. (2007). Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA — PubMed PMID: 17405972
4. Schierbeck LL, Rejnmark L, Tofteng CL, et al. (2012). Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ (Clinical Research Ed.) — PubMed PMID: 23048011
5. Anonymous (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause (New York, N.Y.) — PubMed PMID: 35797481
6. Canonico M, Oger E, Plu-Bureau G, et al. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation — PubMed PMID: 17309934
7. Avis NE, Crawford SL, Greendale G, et al. (2015). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine — PubMed PMID: 25686030
8. Davis SR, Baber R, Panay N, et al. (2019). Global Consensus Position Statement on the Use of Testosterone Therapy for Women. The Journal of Clinical Endocrinology and Metabolism — PubMed PMID: 31498871

PubMed Topic Searches

The following PubMed topic searches aggregate the current peer-reviewed literature. Each link opens a live PubMed query — results update as new studies are indexed.

1. PubMed: Menopause hormone therapy
2. PubMed: Women's Health Initiative
3. PubMed: Transdermal estradiol
4. PubMed: Micronized progesterone
5. PubMed: Vasomotor symptoms menopause
6. PubMed: Genitourinary syndrome of menopause
7. PubMed: Menopause bone density
8. PubMed: Menopause cardiovascular risk
9. PubMed: Menopause cognition
10. PubMed: Testosterone women menopause
11. PubMed: Selective estrogen receptor modulator
12. PubMed: Menopause timing hypothesis

Back to Table of Contents

Featured Videos